INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 141 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $423 | -0.9% | 8,122 | +20.3% | 0.04% | -16.3% |
| Q2 2023 | $427 | +46.7% | 6,751 | +23.0% | 0.04% | +19.4% |
| Q4 2022 | $291 | -99.9% | 5,490 | -40.4% | 0.04% | -30.8% |
| Q1 2021 | $313,000 | +44.9% | 9,216 | -34.4% | 0.05% | -3.7% |
| Q1 2020 | $216,000 | -30.8% | 14,043 | -66.4% | 0.05% | +28.6% |
| Q3 2019 | $312,000 | +119.7% | 41,823 | +236.0% | 0.04% | +162.5% |
| Q4 2018 | $142,000 | -83.5% | 12,449 | -74.4% | 0.02% | -62.8% |
| Q2 2018 | $859,000 | -7.6% | 48,594 | +10.0% | 0.04% | -12.2% |
| Q1 2018 | $930,000 | -42.2% | 44,194 | -60.2% | 0.05% | -50.0% |
| Q4 2017 | $1,609,000 | +648.4% | 111,100 | +687.9% | 0.10% | +716.7% |
| Q3 2016 | $215,000 | -77.9% | 14,100 | -43.8% | 0.01% | -77.8% |
| Q2 2016 | $973,000 | +379.3% | 25,068 | +243.4% | 0.05% | +315.4% |
| Q1 2016 | $203,000 | – | 7,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |